Abstract
Background Chronic hepatitis is an important problem worldwide, associating high morbidity and mortality, and hepatocellular-carcinoma is one of its most severe complications. Multiple studies have tried to identify biomarkers that would allow an earlier detection of hepatocellularcarcinoma (HCC), compared to imagistic exams. Such biomarkers are represented by alpha-fetoprotein (AFP), des-gcarboxy prothrombin (DPC), and the lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3).
Highlights
Chronic hepatitis is an important problem worldwide, associating high morbidity and mortality, and hepatocellular-carcinoma is one of its most severe complications.Multiple studies have tried to identify biomarkers that would allow an earlier detection of hepatocellularcarcinoma (HCC), compared to imagistic exams
The program involves a serum panel performed in the Lotus-MED Medical Center, consisting of AFP, DCP and AFP-L3%, performed at two study visits: screening and 48 weeks follow-up
As the study is still ongoing, we present descriptive data derived from the first study visit
Summary
Serum screening for hepatocellularcarcinoma in patients with hepatitis Alina Cristina Neguț1,2*, Anca Streinu-Cercel, Oana Săndulescu, Mădălina Carap, Mihaela Adriana Toderici, Adrian Streinu-Cercel. From The 10th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof Dr Matei Bals” Bucharest, Romania.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
